May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Quantitative Comparison of Short-Term Anatomic Response Following Pegaptanib versus Bevacizumab Treatment for Neovascular Age-Related Macular Degeneration
P. Romano; S. Joeres; K. Kaplowitz; J. W. Brubaker; P. Updike; A. C. Walsh; S. R. Sadda
Author Affiliations & Notes
  • P. Romano
    Doheny Image Reading Ctr, Doheny Eye Institute, Los Angeles, California
  • S. Joeres
    Doheny Image Reading Ctr, Doheny Eye Institute, Los Angeles, California
  • K. Kaplowitz
    Doheny Image Reading Ctr, Doheny Eye Institute, Los Angeles, California
  • J. W. Brubaker
    McGill University, Montreal, Quebec, Canada
  • P. Updike
    Doheny Image Reading Ctr, Doheny Eye Institute, Los Angeles, California
  • A. C. Walsh
    Doheny Image Reading Ctr, Doheny Eye Institute, Los Angeles, California
  • S. R. Sadda
    Doheny Image Reading Ctr, Doheny Eye Institute, Los Angeles, California
  • Footnotes
    Commercial Relationships P. Romano, None; S. Joeres, None; K. Kaplowitz, None; J.W. Brubaker, None; P. Updike, Topcon Medical Systems, P; A.C. Walsh, Topcon Medical Systems, P; S.R. Sadda, Topcon Medical Systems, P.
  • Footnotes
    Support NIH Grant EY03040
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 270. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Quantitative Comparison of Short-Term Anatomic Response Following Pegaptanib versus Bevacizumab Treatment for Neovascular Age-Related Macular Degeneration
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      P. Romano, S. Joeres, K. Kaplowitz, J. W. Brubaker, P. Updike, A. C. Walsh, S. R. Sadda; Quantitative Comparison of Short-Term Anatomic Response Following Pegaptanib versus Bevacizumab Treatment for Neovascular Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2007;48(13):270.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose:: To compare the morphologic effect of pegaptanib (MacugenTM) versus bevacizumab (AvastinTM) treatment in neovascular age-related macular degeneration (AMD) using computer-assisted grading software for enhanced quantitative analysis of optical coherence tomography (OCT) images.

Methods:: The raw exported Stratus OCT scan data of consecutive cases undergoing intravitreal pegaptanib (18 eyes) or bevacizumab (35 eyes) treatment for AMD were retrospectively collected. OCT images were analyzed using custom software (OCTOR) designed to calculate thickness and volume of various spaces after manual grading of retinal and subretinal layers. Thickness and volume values of the retina, subretinal fluid (SRF), subretinal tissue (SRT), and pigment epithelial detachments (PEDs) before, and 3 months after, treatment were calculated and compared between both groups. Additionally, results from manual grading were compared against the corresponding automated Stratus OCT output.

Results:: Foveal central subfield (FCS) retinal volumes decreased from 0.26 mm³ to 0.21 mm³ (19% reduction) in the bevacizumab group and remained unchanged at 0.22 mm³ in the pegaptanib group 3 months after injection. Total retinal volume (subfields 1-9) decreased by 0.89 mm³ in the bevacizumab compared to only 0.07 mm³ in the pegaptanib group. Mean SRF, SRT, and PED volumes decreased by 53%, 35%, and 45%, respectively following bevacizumab. In contrast, following pegaptanib, mean SRF decreased by 47%, mean SRT and PED volume actually increased by 9% and 83% at 3 months. Automated Stratus output measurements showed only a small difference (mean decrease of FCS retinal volume 0.05 mm³ after bevacizumab compared to 0.04 mm³ after pegaptanib) between both treatments in this series due to frequent incorrect retinal boundary detection.

Conclusions:: Short term results suggest that intravitreal bevacizumab is associated with an improved anatomical outcome compared to pegaptanib treatment, particularly in reducing SRT and PEDs. Sub-analysis of OCT data may be useful in studying the differential morphologic effects of various treatments.

Keywords: age-related macular degeneration • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • macula/fovea 
© 2007, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept